Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
Clinical trial data from Eli Lillys Phase 2 study showed that the 12mg weekly dose produced an average weight loss of 24.2% over 48 weeks, with over 80% of participants losing at least 15% of their starting body weight
People taking GLP-1 receptor agonists may become dehydrated from vomiting or diarrhea, causing kidney problems
At GoodRx we estimate that in the last year Americans have overspent by at least $200 million by paying full retail price for their weight-loss GIP and GLP-1 agonists
US$ 29.56
US$ 27.24
US$ 22.43
US$ 20.29
US$ 25.65
